Pulse biosciences, inc. (PLSE)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15
Cash flows from operating activities:
Net loss

-46,971

-37,545

-25,567

-9,518

-2,811

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

494

645

336

94

51

Amortization of intangible assets

666

665

665

665

666

Loss on disposal of fixed assets

-

-28

-

-

-

Stock-based compensation

11,287

12,338

10,926

870

402

Net premium amortization and discount on available-for-sale securities

521

140

-26

-4

-

Landlord incentive for tenant improvements

-

-

2,119

-

-

Change in deferred income taxes

-

-

-

-

-1,657

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

226

367

144

415

12

Right-of-use assets

-68

-

-

-

-

Other long-term assets

393

-

101

-

-

Deferred offering costs

-

-

-

-

347

Accounts payable

646

490

517

3

125

Accrued expenses

841

387

245

246

305

Lease liabilities

-76

-

-

-

-

Other current and non-current liabilities

-

-397

-109

-

-

Deferred grant revenue

-

-

-

-

-39

Net cash used in operating activities

-34,185

-23,896

-11,087

-8,051

-3,317

Cash flows from investing activities:
Purchases of property and equipment

608

276

2,551

64

86

Purchases of investments

77,993

40,297

43,595

19,067

-

Maturities of investments

68,500

41,815

23,148

4,750

-

Sales of investments

-

24,875

-

-

-

Net cash provided by (used) in investing activities

-10,101

26,117

-22,998

-14,381

-86

Cash flows from financing activities:
Proceeds from exercises of stock options and warrants

272

498

539

-

-

Proceeds from issuance of common stock from private placements, net of issuance costs of $199

-

-

34,843

-

-

Proceeds from issuance of common stock from initial public offering, net of issuance costs

-

-

-

20,915

-

Proceeds from issuance of common stock under employee stock purchase plan

423

327

-

-

-

Proceeds from issuance of common stock from rights offering, net of issuance costs of $213

-

44,786

-

-

-

Tax payments related to shares withheld for vested restricted stock units

613

115

-

-

-

Net cash provided by financing activities

82

45,496

35,382

20,915

-

Net increase (decrease) in cash

-44,204

47,717

1,297

-

-

Net increase (decrease) in cash

-

-

-

-1,517

-3,403

Supplemental disclosure of noncash investing and financing activities:
Reclassification of deferred offering costs to additional paid-in capital upon initial public offering

-

-

-

627

-

Equipment purchases included in accounts payable and accrued expenses

279

33

38

18

104